Ujin Pharma Files for IPO Featuring 11.9 Million Fresh Shares

Ashik Bothra - Mumbai Bureau Jun 22, 2026 4,450 Views

Ujin Pharma Limited has filed its draft prospectus with SEBI to launch an initial public offering. The upcoming issue contains a fresh issuance of up to 11.9 million equity shares to fund manufacturing expansion and debt reduction, paired with an Offer for Sale of up to 7.3 million shares from existing stakeholders.

MUMBAI, INDIA — Ujin Pharma Limited has formally filed its Draft Red Herring Prospectus (DRHP) with capital market watchdogs to execute an initial public offering (IPO). According to statutory compliance papers made public today, June 22, 2026, the proposed public transaction is configured through a dual-track equity strategy. The primary component consists of a fresh issue of up to 11.9 million newly minted common shares. Concurrently, the secondary component features an Offer for Sale (OFS) where existing institutional shareholders and promoter groups will offload up to 7.3 million equity shares.

The public filing arrives during a period of intense capital generation across India's active pharmaceutical ingredient (API) and contract development sectors. By floating this structured equity offering on domestic exchanges, the company aims to clear outstanding debt, finance specialized production facility upgrades, and capitalize on expanding healthcare supply chains across global markets.

Dual Offering Balance Minimizes Post-Listing Capitalization Pressure

According to regulatory frameworks reviewed by listing teams on the Securities and Exchange Board of India (SEBI) electronic filing gateway, the structured combination of fresh shares and secondary volumes protects post-listing ratios. The newly minted 11.9 million share pool will channel growth capital directly into the corporate balance sheet. In contrast, the 7.3 million shares allocated under the Offer for Sale route will be paid directly to the divesting stakeholders, meaning the parent entity will not receive any capital proceeds from the secondary pool.

Investment banking analysts from Mumbai exchange desks note that splitting the offering helps the company manage its post-issue equity structure. The layout gives early institutional venture funds a regulated, transparent exit option while simultaneously limiting excessive share dilution for upcoming retail and public market investors.

Funding Targets Multi-State Production and Research Expansions

The financial proceeds generated by the 11.9 million fresh share issuance have been mapped out under strict corporate expenditure mandates. The primary allocation will fund a state-of-the-art manufacturing expansion designed to scale up the company's chemical synthesis lines. This infrastructure boost will help the firm meet growing international demand for complex active pharmaceutical ingredients and high-grade intermediates used in chronic care therapies.

A secondary portion of the primary capital will be routed directly to pay down interest-bearing commercial bank borrowings. Clearing these obligations will reduce fixed financial overheads, helping the company improve its debt-to-equity ratio and protect its operating margins. The remaining proceeds are earmarked for general corporate purposes, including funding advanced drug master file (DMF) regulatory applications in highly regulated Western export markets.

Official Sources Section

The corporate blueprints, operational metrics, and initial share parameters have been processed through verified capital market oversight portals.

Market Regulator: Securities and Exchange Board of India (SEBI) Public Disclosures.
Filing Class: Draft Red Herring Prospectus (DRHP) Submission.
Book Running Managers: Designated Indian Institutional Investment Banks.

Quote Section

"According to officials familiar with the transaction details, the final price band and exact bidding windows will be determined sequentially following SEBI's technical clearance of the draft prospectus. Market organizers stated that the equity allocation will feature standard institutional reservation rules, splitting availability across Qualified Institutional Buyers, Non-Institutional Investors, and retail individuals."

Why It Matters

For public market investors, the balanced IPO structure provides a transparent path to participate in India's expanding pharmaceutical export market. For healthcare supply networks, Ujin Pharma's planned facility upgrades ensure a more resilient domestic supply of critical active ingredients. This self-sufficiency reduces production reliance on raw chemical imports and helps keep downstream generic medicines affordable for everyday consumers.

Key Facts at a Glance

Primary Share Inflow: The IPO features a fresh issue of up to 11.9 million newly minted common shares.
Secondary Divestment: Includes an Offer for Sale (OFS) of up to 7.3 million shares from existing holders.
Capital Utilization: Funds will be used for production expansions, R&D equipment sourcing, and debt reduction.
Regulatory Status: The Draft Red Herring Prospectus has been officially logged with SEBI for compliance screening.

FAQ Section

What is the core distinction between the fresh issue and the Offer for Sale in this IPO?

The 11.9 million fresh issue shares represent new equity created by the company, meaning the proceeds go directly onto the balance sheet to fund expansion. The 7.3 million OFS shares belong to existing investors, meaning those sale proceeds go directly to the individuals selling their stakes.

Can individual retail investors apply for shares in this public issue?

Yes. Under standard SEBI listing regulations, a designated slice of the total public issue size will be explicitly reserved for small-scale retail individual investors, managed via the unified application interface.

Where does Ujin Pharma operate its core research and manufacturing hubs?

The firm coordinates its industrial chemical processing networks and research facilities across specialized manufacturing clusters situated in major industrial zones in India.

Source: